Innova Captab Limited Reports Robust Financial Growth for Q4 and FY26

Innova Captab Limited has announced strong financial performance for the quarter and financial year ended March 31, 2026. The company achieved a 42.3% year-on-year revenue growth in Q4, reaching ₹447.8 crore, while annual revenue for FY26 climbed 31.1% to ₹1,630.0 crore. This growth was driven by disciplined execution in the CDMO and branded generics segments, alongside significant expansion in its state-of-the-art manufacturing capabilities and key international regulatory certifications.

Financial Performance Highlights

For the quarter ended March 31, 2026, Innova Captab Limited recorded a strong performance with revenue from operations reaching ₹447.8 crore, marking a significant 42.3% increase compared to the same period last year. EBITDA for the quarter stood at ₹66.7 crore, reflecting a 30.5% growth. Profit After Tax (PAT) for the quarter rose by 28.8% to ₹38.1 crore.

On an annual basis, the company achieved its highest-ever revenue of ₹1,630.0 crore for FY26, representing a 31.1% year-on-year growth. Annual EBITDA was reported at ₹250.3 crore, a 26.3% increase, while the full-year PAT reached ₹140.9 crore.

Operational Milestones and Strategic Growth

The company’s growth trajectory was supported by its CDMO and branded generics businesses. Managing Director Mr. Vinay Lohariwala attributed the milestone performance to disciplined operational execution and an expanding product portfolio. A key highlight for the year was the advancement of the Jammu facility, which completed its first full year of operations and is successfully scaling up to meet demand from marquee clients.

Enhanced Regulatory Presence

Innova Captab continues to strengthen its footprint in regulated markets. During FY26, the company reached critical milestones by securing UK-MHRA certification for its Baddi facility and PIC/S accreditation for its Jammu blocks. These certifications, alongside the company’s five state-of-the-art manufacturing facilities, position the organization to continue its momentum in delivering high-quality healthcare solutions to its 350+ clients globally.

Source: BSE

Previous Article

Voltas Board Meeting Scheduled to Review Q4 and FY26 Financial Results

Next Article

Alivus Life Sciences Limited Annual Secretarial Compliance Report for FY 2025-26